The impact of omega-3 fatty acids on depressive disorders and suicidality: can we reconcile 2 studies with seemingly contradictory results?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Trim the fat: the role of omega-3 fatty acids in psychopharmacology.Therapeutic advances in psychopharmacology · 2019
   Review
2. The Role of Physical Exercise and Omega-3 Fatty Acids in Depressive Illness in the Elderly.Current neuropharmacology · 2018
   Review
3. Fish oil and depression: The skinny on fats.Journal of integrative neuroscience · 2017
   Review
4. Perinatal depression and omega-3 fatty acids: a Mendelian randomisation study.Journal of affective disorders · 2014
   Article
5. Current evidence for the clinical use of long-chain polyunsaturated n-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease.The journal of nutrition, health & aging · 2013
   Article
6. The serotonergic system in mood disorders and suicidal behaviour.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2013
   Review

Corrections and comments

• Comment on
  Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry.2006
• Comment on
  A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids.2007
• Comment on
  A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder.2009
• Comment on
  Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.2010
• Comment on
  Suicide deaths of active-duty US military and omega-3 fatty-acid status: a case-control comparison.2011
• Comment on
  Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression.2011
• Comment on
  Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression.2012

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as